Degrader Antibodies for Plasma Cells: Mechanisms, Clinical Potential, and Emerging Therapies

Abstract

Degrader antibodies represent an innovative therapeutic approach targeting plasma cells, particularly in conditions mediated by pathological antibody production such as multiple myeloma and refractory autoimmune diseases. This review synthesizes current scientific understanding of degrader antibody mechanisms, explores their clinical relevance, and examines recent advances in their development. Special attention is given to disease epidemiology, pathophysiology, diagnostic strategies, and guideline recommendations, providing a comprehensive overview for clinicians and healthcare professionals seeking to integrate novel biologics into practice.

Introduction

Plasma cells play a pivotal role in humoral immunity by producing antibodies; however, aberrant plasma cell proliferation or function is central to the pathogenesis of various malignancies and autoimmune disorders. Traditional therapies for plasma cell dyscrasias have focused on cytotoxic agents, proteasome inhibitors, and monoclonal antibodies, but resistance and relapse remain significant challenges. Degrader antibodies, a class of engineered biologics capable of inducing targeted intracellular protein degradation, have emerged as a promising therapeutic modality. This review aims to provide a detailed analysis of the scientific rationale, clinical applications, and practical implications of degrader antibodies for plasma cells.

Epidemiology / Disease Burden

Disorders involving pathological plasma cells, such as multiple myeloma, Waldenström macroglobulinemia, and certain refractory autoimmune diseases (e.g., systemic lupus erythematosus, autoimmune hemolytic anemia), collectively contribute to substantial morbidity and mortality worldwide. Multiple myeloma alone has an estimated global incidence of over 160,000 new cases annually, with a rising prevalence due to increased survival and aging populations. Autoimmune plasma cell-mediated diseases affect millions, often with relapsing and remitting courses that complicate management. The unmet clinical need for more selective and durable therapies underpins ongoing research into novel agents such as degrader antibodies.

Pathophysiology

Pathological plasma cells are characterized by dysregulated survival, excessive immunoglobulin production, and resistance to apoptosis. In malignancies, genomic instability and microenvironmental factors—such as cytokine signaling and bone marrow stromal support—drive proliferation and drug resistance. In autoimmune diseases, autoreactive plasma cells escape normal tolerance checkpoints, producing pathogenic autoantibodies. Targeted protein degradation leverages the cell’s own proteolytic machinery (e.g., ubiquitin-proteasome system) to selectively eliminate disease-driving proteins, thereby circumventing traditional resistance mechanisms and potentially restoring immune homeostasis.

Risk Factors

Risk factors for plasma cell dyscrasias and related disorders include advanced age, genetic predisposition (such as germline or somatic mutations in immunoglobulin or oncogene loci), chronic immune stimulation, and environmental exposures (ionizing radiation, certain chemicals). In autoimmune conditions, factors such as genetic background (e.g., HLA subtypes), infections, and dysregulated immune checkpoints contribute to disease onset and progression. Understanding these risk factors is essential for identifying patient populations that may benefit most from degrader antibody therapies.

Clinical Features

Clinical manifestations vary by underlying disease. Multiple myeloma classically presents with bone pain, anemia, renal dysfunction, hypercalcemia, and recurrent infections. Autoimmune plasma cell disorders may manifest as cytopenias, organ-specific dysfunction, and systemic inflammatory symptoms. Disease course can range from indolent to rapidly progressive, necessitating individualized therapeutic strategies. The clinical burden underscores the importance of therapies that offer both efficacy and safety, minimizing off-target effects and preserving essential immune function.

Diagnosis

Diagnosis relies on a combination of clinical assessment, laboratory evaluation (serum protein electrophoresis, immunofixation, free light chain analysis), bone marrow biopsy, and advanced imaging (MRI, PET-CT). Flow cytometry and molecular diagnostics help characterize clonal populations and guide risk stratification. In the context of emerging therapies, biomarker development is increasingly important for patient selection and monitoring therapeutic response, especially for agents like degrader antibodies with novel mechanisms of action.

Treatment & Management

Conventional treatment options include alkylating agents, immunomodulatory drugs, proteasome inhibitors, anti-CD38 and anti-SLAMF7 monoclonal antibodies, corticosteroids, and stem cell transplantation. These modalities, while effective in many cases, are frequently limited by toxicity, resistance, and relapse. Management of plasma cell-driven autoimmunity often involves immune suppression, with associated risks of infection and long-term morbidity. The advent of targeted therapies, including degrader antibodies, seeks to improve outcomes by selectively eliminating pathogenic plasma cells or their critical molecular drivers.

Recent Advances / Emerging Therapies

Degrader antibodies function through mechanisms such as proteolysis-targeting chimeras (PROTACs) and lysosome-targeting agents, which facilitate the selective degradation of intracellular proteins essential for plasma cell survival and function. Preclinical studies have demonstrated potent activity against both malignant and autoreactive plasma cells, with early-phase clinical trials underway. Key targets include transcription factors (IRF4, MYC), surface antigens (CD38, BCMA), and signaling molecules critical to plasma cell viability. These agents offer the potential for deeper and more sustained remissions, and may overcome resistance to conventional therapies. Ongoing research focuses on optimizing pharmacokinetics, minimizing immunogenicity, and identifying synergistic combinations with existing drugs.

Guideline Recommendations

Current guidelines from major hematology and rheumatology societies emphasize individualized risk-adapted therapy for plasma cell disorders, incorporating novel agents as data mature. While degrader antibodies are not yet standard of care, their inclusion in clinical trial protocols is encouraged for eligible patients with relapsed or refractory disease. Early-phase data should be interpreted cautiously, and multidisciplinary management—including consultation with clinical pharmacologists and immunologists—is recommended to optimize integration into practice. Ongoing surveillance for adverse events and long-term outcomes is critical as these therapies transition from experimental to mainstream use.

Conclusion

Degrader antibodies herald a new era in the targeted treatment of plasma cell-driven diseases, offering hope for more effective and durable responses with reduced toxicity. Their rational design, grounded in molecular pathology, enables a precision medicine approach that may ultimately redefine the therapeutic landscape for multiple myeloma, refractory autoimmune disorders, and related conditions. Continued translational research, robust clinical trials, and vigilant post-marketing surveillance will be essential to fully realize their potential and establish their role in contemporary medical practice.